VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction

VelaShape is a non-invasive (not breaking the skin) device for Body Reshaping and Cellulite Treatment. VelaShape combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.

The CoolSculpt System is a noninvasive device that reduces fat by freezing fat cells until they break apart.

Inclusion criteria

• Informed consent process completed and subject completed consent.
• Fitzpatrick Skin Type I to VI
• Having excess fat deposits bilaterally in the waist / love-handle / flank areas.
• BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
• Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
• Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
• If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
• Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

Exclusion criteria

• Subjects with history of excessive weight fluctuation or expect to gain/lose more than 5 pounds) during the study time frame.
• Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
• Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
• Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
• Known photosensitivity.
• Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
• Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
• Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
• Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
• Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
• History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
• Suffering from hormonal imbalance which may affect weight as per the Investigator's discretion.
• History of significant lymphatic drainage problems or impaired circulation in the area to be treated.
• Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
• History of keloid scarring, abnormal wound healing and / or prone to bruising.
• History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
• Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
• Allergy to any component of the lotion (VelaSpray Ease) used in this study.
• Cryoglobulinemia, Paroxysmal cold hemoglobinuria, or any known sensitivity to cold such as cold urticaria or Raynaud's disease.
• Neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy, or impaired skin sensation in the area to be treated.
• Hernia in the area to be treated.
• Participation in a study of another device or drug within 9 month prior to enrollment or during this study, if the treated area was involved.
• As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.